Dendritic cells and immune cytokine network

Dendritic cells (DCs) are specialized antigen-presenting cells that serve as the primary link between innate and adaptive immunity [NIH]. They function by capturing, processing, and presenting antigens to T cells, a process heavily regulated by a complex network of immune cytokines [PubMed]. This cytokine network, including molecules like IL-12, IL-23, and Type I Interferons, dictates the maturation of DCs and the subsequent polarization of T-cell responses [Nature Reviews Immunology]. In disease states, dysregulation of this network can lead to chronic inflammation, autoimmunity, or the failure of the immune system to recognize malignant cells [StatPearls]. While not a single molecular target, the DC-cytokine axis is a major focus of therapeutic intervention, with drugs designed to either inhibit specific pro-inflammatory cytokines or enhance DC activity through vaccination [NCBI]. For example, biologics targeting IL-12 and IL-23 are used to treat autoimmune conditions like psoriasis, while DC-based vaccines are explored in oncology to trigger anti-tumor T-cell activity [FDA]. Because this term encompasses a broad biological system and multiple distinct molecular entities, it is classified as a cellular network rather than a specific therapeutic target.

Other names

Dendritic cell-cytokine axisDC-cytokine networkDendritic cell-mediated immune signaling

Modulation of dendritic cell maturation, antigen presentation, and cytokine-mediated signaling to regulate the balance between immune activation and tolerance [Nature Reviews Immunology].